S&P 500   3,998.84
DOW   33,947.10
QQQ   287.64
All the Cloud Storage You Need Is on Sale for the Holidays
China Threat Triggers Potential Mining Boom for Investors (Ad)
Tesla Shares Are Sliding, Here’s Why
Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
Why is Russia reopening dormant copper mines? (Ad)
Lockheed teams with Israel's Rafael on laser defense
Russian oil price cap, EU ban aim to limit Kremlin war chest
Why is Russia reopening dormant copper mines? (Ad)
World Cup fans find booze at hotels, Qatar's 1 liquor store
3 Signs the Stock Market Outlook is Improving
S&P 500   3,998.84
DOW   33,947.10
QQQ   287.64
All the Cloud Storage You Need Is on Sale for the Holidays
China Threat Triggers Potential Mining Boom for Investors (Ad)
Tesla Shares Are Sliding, Here’s Why
Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
Why is Russia reopening dormant copper mines? (Ad)
Lockheed teams with Israel's Rafael on laser defense
Russian oil price cap, EU ban aim to limit Kremlin war chest
Why is Russia reopening dormant copper mines? (Ad)
World Cup fans find booze at hotels, Qatar's 1 liquor store
3 Signs the Stock Market Outlook is Improving
S&P 500   3,998.84
DOW   33,947.10
QQQ   287.64
All the Cloud Storage You Need Is on Sale for the Holidays
China Threat Triggers Potential Mining Boom for Investors (Ad)
Tesla Shares Are Sliding, Here’s Why
Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
Why is Russia reopening dormant copper mines? (Ad)
Lockheed teams with Israel's Rafael on laser defense
Russian oil price cap, EU ban aim to limit Kremlin war chest
Why is Russia reopening dormant copper mines? (Ad)
World Cup fans find booze at hotels, Qatar's 1 liquor store
3 Signs the Stock Market Outlook is Improving
S&P 500   3,998.84
DOW   33,947.10
QQQ   287.64
All the Cloud Storage You Need Is on Sale for the Holidays
China Threat Triggers Potential Mining Boom for Investors (Ad)
Tesla Shares Are Sliding, Here’s Why
Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
Why is Russia reopening dormant copper mines? (Ad)
Lockheed teams with Israel's Rafael on laser defense
Russian oil price cap, EU ban aim to limit Kremlin war chest
Why is Russia reopening dormant copper mines? (Ad)
World Cup fans find booze at hotels, Qatar's 1 liquor store
3 Signs the Stock Market Outlook is Improving
NASDAQ:PIRS

Pieris Pharmaceuticals - PIRS Stock Forecast, Price & News

$0.99
-0.01 (-1.00%)
(As of 12/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.95
$1.00
50-Day Range
$0.94
$1.19
52-Week Range
$0.92
$4.08
Volume
147,024 shs
Average Volume
372,527 shs
Market Capitalization
$73.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PIRS stock logo

About Pieris Pharmaceuticals (NASDAQ:PIRS) Stock

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

Receive PIRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PIRS Stock News Headlines

Recap: Pieris Pharmaceuticals Q3 Earnings
PIRS Pieris Pharmaceuticals, Inc.
See More Headlines
Receive PIRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PIRS Company Calendar

Last Earnings
11/02/2022
Today
12/05/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/07/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PIRS
Employees
124
Year Founded
N/A

Profitability

Net Income
$-45,740,000.00
Net Margins
-121.78%
Pretax Margin
-121.78%

Debt

Sales & Book Value

Annual Sales
$31.42 million
Book Value
$0.70 per share

Miscellaneous

Free Float
68,974,000
Market Cap
$73.59 million
Optionable
Optionable
Beta
1.01

Key Executives

  • Mr. Stephen S. Yoder J.D. (Age 46)
    CEO, Pres & Director
    Comp: $834.16k
  • Dr. Hitto Kaufmann Ph.D. (Age 51)
    Sr. VP & Chief Scientific Officer
    Comp: $520.29k
  • Mr. Thomas Bures (Age 48)
    Sr. VP & CFO
  • Maria Kelman
    Exec. Director of Investor Relations
  • Mr. Ahmed S. Mousa J.D. (Age 37)
    Sr. VP, Chief Bus. Officer, Gen. Counsel & Corp. Sec.
  • Mr. Frank Vollmering
    VP of HR
  • Dr. Christine Rothe Ph.D.
    VP and Head of Early Stage Project Leadership & Data Science
  • Dr. Shane Olwill Ph.D. (Age 46)
    Sr. VP & Chief Devel. Officer
  • Mr. Prompong Chaikul (Age 35)
    Chief Supply Chain Officer
  • Dr. Gordon Otto M.D.
    Ph.D., Head of Clinical Devel. Oncology













PIRS Stock - Frequently Asked Questions

How have PIRS shares performed in 2022?

Pieris Pharmaceuticals' stock was trading at $3.78 at the start of the year. Since then, PIRS shares have decreased by 74.0% and is now trading at $0.9845.
View the best growth stocks for 2022 here
.

When is Pieris Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our PIRS earnings forecast
.

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) posted its earnings results on Wednesday, November, 2nd. The biotechnology company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03. The biotechnology company had revenue of $5.37 million for the quarter, compared to analysts' expectations of $4.51 million. Pieris Pharmaceuticals had a negative net margin of 121.78% and a negative trailing twelve-month return on equity of 75.31%.

What other stocks do shareholders of Pieris Pharmaceuticals own?
What is Pieris Pharmaceuticals' stock symbol?

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

Who are Pieris Pharmaceuticals' major shareholders?

Pieris Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Lynx1 Capital Management LP (4.72%), Marshall Wace LLP (3.28%), Platinum Investment Management Ltd. (1.64%), Renaissance Technologies LLC (0.98%), Jacobs Levy Equity Management Inc. (0.53%) and Connor Clark & Lunn Investment Management Ltd. (0.18%). Insiders that own company stock include Aquilo Capital Management, Llc, Shane Olwill and Tim Demuth.
View institutional ownership trends
.

How do I buy shares of Pieris Pharmaceuticals?

Shares of PIRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pieris Pharmaceuticals' stock price today?

One share of PIRS stock can currently be purchased for approximately $0.98.

How much money does Pieris Pharmaceuticals make?

Pieris Pharmaceuticals (NASDAQ:PIRS) has a market capitalization of $73.25 million and generates $31.42 million in revenue each year. The biotechnology company earns $-45,740,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis.

How many employees does Pieris Pharmaceuticals have?

The company employs 124 workers across the globe.

How can I contact Pieris Pharmaceuticals?

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The official website for the company is www.pieris.com. The biotechnology company can be reached via phone at (857) 246-8998, via email at kelman@pieris.com, or via fax at 49-8161-141-1444.

This page (NASDAQ:PIRS) was last updated on 12/6/2022 by MarketBeat.com Staff